IL37 and psoriasis: A systematic review on the rapidity of onset of action for IL-17 and IL-23 inhibitors for psoriasis demonstrated that the time to onset of action for brodalumab was 2.1–2.6, and 2.2–2.3 weeks for ixekizumab, which were quicker than tildrakizumab (5.6–5.7 weeks), secukinumab (3.0–4.3 weeks), and guselkumab (3.8 weeks) (144).